[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100358314":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":33,"locations":43,"responsibleParty":61,"collaborators":63,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":71,"sex":77,"minAge":78,"maxAge":32,"enrollmentInfo":79,"targetDuration":32,"studyType":82,"phases":83,"briefSummary":86,"conditions":87,"keywords":32,"overallStatus":46,"whyStopped":32,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Makerere University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Single dose liposomal Amphotericin and fluconazole","EXPERIMENTAL","Experimental:\n\nSingle dose Ambisome 10mg\u002Fkg and Fluconazole 800mg for two weeks ,400mg for 8 weeks and 200mg upto 6 months. (standard of care therapy)",[13],"Drug: Single dose liposomal Amphotericin and Fluconazole",{"label":15,"type":16,"description":17,"interventionNames":18},"fluconazole (standard of care)","ACTIVE_COMPARATOR","Standard of care pre-emptive treatment fluconazole 800mg for two weeks ,400mg for 8 weeks and 200mg upto 6 months",[19],"Drug: Fluconazole",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Single dose liposomal Amphotericin and Fluconazole","Intravenous Single dose of 10mg\u002Fkg of Ambisome and fluconazole as per WHO guidelines for six months.",[9],[27],"AMBISOME and fluconazole",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Fluconazole","Fluconazole 800mg for 2 weeks,400mg for 8 weeks and 200mg up to six months",[15],null,[34,39],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":38},"DAVID MEYA, PhD","CONTACT","+256 772 543 730","david.meya@gmail.com",{"name":40,"role":36,"phone":41,"phoneExt":32,"email":42},"ELIZABETH NALINTYA, MPH","+256 771 321 617","enalintya@idi.co.ug",[44],{"facility":45,"status":46,"city":47,"state":32,"zip":32,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"infectious Disease Institute Kampala,Uganda","RECRUITING","Kampala","Uganda","UG",{"type":51,"coordinates":52},"Point",[53,54],32.58219,0.31628,{"lat":54,"lon":53},[57,58,59],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":38},{"name":40,"role":36,"phone":41,"phoneExt":32,"email":42},{"name":35,"role":60,"phone":32,"phoneExt":32,"email":32},"PRINCIPAL_INVESTIGATOR",{"type":62,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR",[64,66],{"name":65,"class":6},"University of Minnesota",{"name":67,"class":68},"Gilead Sciences","INDUSTRY","100358314","phase-2-single-dose-liposomal-amphotericin-for-asymptomatic-cryptococcal-antigenemia-100358314",false,"NCT03945448","Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia","Evaluation of CrAg Screening With Enhanced Antifungal Therapy for Asymptomatic CrAg+ Persons","ACACIA","Inclusion Criteria:\n\n* HIV-1 infection\n* Age \\> or equal to15 years\n* Ability and willingness to give informed consent.\n* Plasma\u002FSerum cryptococcal antigen (CRAG)+ with a titer 1:160 or greater\n\nExclusion Criteria:\n\n* Cannot or unlikely to attend regular clinic visits\n* History of cryptococcal infection\n* Symptomatic meningitis (confirmed by CSF CRAG+)\n* \\>14 days of fluconazole therapy\n* Pregnancy (confirmed by urinary or serum pregnancy test)\n* Current breastfeeding\n* Known allergy to amphotericin","ALL","15 Years",{"count":80,"type":81},356,"ESTIMATED","INTERVENTIONAL",[84,85],"PHASE2","PHASE3","This will be a randomized controlled trial of asymptomatic (Cryptococcal Antigen test)CrAg positive persons in Uganda.\n\nPatients will be randomized to receive preemptive treatment with 1 dose of liposomal amphotericin (10mg\u002Fkg) in addition to standard of care fluconazole therapy.\n\nHow the enhanced antifungal therapy prevents progression to meningitis in the first 24-weeks and overall survival in those who receive the intervention compared with participants receiving fluconazole per World Health Organisation (WHO) and national standard of care therapy will be evaluated.",[88],"Cryptococcal Meningitis","2026-04-27",{"date":91,"type":92},"2026-04-28","ACTUAL",{"date":94,"type":92},"2019-06-20",{"date":96,"type":81},"2027-08",{"name":5,"class":6},1]